Compare ENTX & LSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTX | LSBK |
|---|---|---|
| Founded | 2010 | 1891 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 135.5M |
| IPO Year | 2015 | 2025 |
| Metric | ENTX | LSBK |
|---|---|---|
| Price | $3.00 | $17.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 324.6K | 8.5K |
| Earning Date | 05-14-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 2.27% |
| EPS Growth | N/A | ★ 49.23 |
| EPS | 0.22 | ★ 0.56 |
| Revenue | ★ $42,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $13.39 | $31.11 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $12.50 |
| 52 Week High | $4.20 | $17.96 |
| Indicator | ENTX | LSBK |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 63.94 |
| Support Level | $2.66 | $16.68 |
| Resistance Level | $3.10 | $17.56 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 19.09 | 89.16 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.